Anavex Life Sciences Corp (AVXL)

[Steady_T]

The CHMP plays a vital role in the authorisation of medicines in the European Union (EU).

Centralised procedure
In the centralised procedure, the CHMP is responsible for:

conducting the initial assessment of EU-wide marketing authorisation applications;
assessing modifications or extensions ('variations') to an existing marketing authorisation;
considering the recommendations of the Agency's Pharmacovigilance Risk Assessment Committee on the safety of medicines on the market and when necessary, recommending to the European Commission changes to a medicine's marketing authorisation, or its suspension or withdrawal from the market.